• Estyka Ratu Internship Doctor Program (medical doctor) Rumah Sakit Bhayangkara and Puskesmas Kalasan, Yogyakarta, Indonesia.




Introduction – Major Depressive Disorder (MDD) is a chronic mental health disorder, with suicidal ideation, but until now an exact diagnostic approach has not been found. For the limitations of the current diagnosis, such as subjective reports of patients or their families with mental status examinations, there is still a lack of objective diagnostic results. In this case, it is still a challenge for researchers. Neutropic factors, hypothalamic-pituitary-adrenal hormones (HPA), indicators of inflammation, and metabolic factors, were found to be novel biomarkers for MDD. However, these biomarkers show limited sensitivity and specificity. The most recent diagnostic development effort is the use of microRNA as a diagnostic modality approach for MDD.

Methods – This study uses a qualitative method by collecting valid journals with certain inclusion and exclusion criteria. The keywords used were MDDmicroRNA, and Diagnostic. There are journals used as the source of this literature review which come from valid scientific sources such as NCBI, ScienceDirect, and PubMed which were published in the last 10 years.

Results – The results of the miRNA-124-3p expression test showed a significant difference between the healthy control group and the MDD patient group. The specificity and sensitivity of miRNA-221-3p, miRNA-451a, miRNA-34a-5p, and let-7d-3p showed high accuracy in the diagnosis of MDD.

Discuss – The unknown etiology of MDD makes some patients have no results or significant progress of their depression in clinical settings which is contributed by gene regulatory pathway that shows high significance associated with neural function brain in depressive disorders such as apoptotic pathway, P13K-Akt signaling, axon guidance, neurotrophin signaling pathway, mTOR signaling pathway.

Conclusion- The diagnostic effectiveness of miRNA in major depressive disorder can be significantly enhanced by using miRNA expression coding and has been proven by various tests. Therefore, this research is expected to be an innovation in diagnosing MDD for further research.

Keywords: MDD, depression, microRNA, diagnostic


Otte, C. et al.“Major depressive disorder,” Nature Reviews Disease Primers. Macmillan Publishers Limited. (2016). doi: 10.1038/nrdp.2016.65.

World Health Organization. Depression: A Global Public Health Concern. Geneve: World Health Organization (2015).

Riset Kesehatan Dasar (Riskesdas). Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018.

Kessler, R. C. The effects of stressful life events on depression. Annu. Rev. Psychol. 48, (2007): 191–214.

Boschloo, L. et al. The four-year course of major depressive disorder: the role of staging and risk factor determination. Psychother. Psychosom. 83, (2014): 279–288.

Ormel, J., Oldehinkel, A. J., Nolen, W. A. & Vollebergh, W. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch. Gen. Psychiatry 61, (2004): 387–392.

Beekman ATF, Spijker J. Personalised diagnosis and treatment of depression. Tijdschr Psychiatr. 2018;60(3):156–160.

Xu T, Fang Y, Rong A, et al. Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy. BMC Med Res Methodol. (2015);15:94. doi:10.1186/s12874-015-0085-z

Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat. (2017);13:1245–1262. doi:10.2147/NDT.S114542

Cao DD, Lu L, Chan WY. MicroRNAs: key regulators in the central nervous system and their implication in neurological diseases. Int J Mol Sci. (2016);17(6):842. doi:10.3390/ijms17060842

Tavakolizadeh J, Roshanaei K, Salmaninejad A, et al. MicroRNAs and exosomes in depression: potential diagnostic biomarkers. J Cell Biochem. (2017);119(5):3783–3797.

Zhang Y, Zhang D, Wang F, et al. Serum miRNAs panel (miR-16- 2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Sci Rep. (2015);5:17942. doi:10.1038/srep17942

Maffifioletti E, Tardito D, Gennarelli M, et al. Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Front Cell Neurosci. (2014);8(8):75. doi:10.3389/fncel.2014.00075.

Pan B, Liu Y. Effects of duloxetine on microRNA expression profifile in frontal lobe and hippocampus in a mouse model of depression. Int J Clin Exp Pathol. (2015);8(11):15454–15461.

Molendijk, M. L. et al. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (n=9484). Mol. Psychiatry 19, (2014):791–800.

Egeland, M., Zunszain, P. A. & Pariante, C. M. Molecular mechanisms in the regulation of adult neurogenesis during stress. Nat. Rev. Neurosci. 16, (2015):189–200.

Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet. (2008); 9:831–842. doi: 10.1038/nrg2455 PMID: 18852696

Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. (2010); 11: 597–610. doi: 10.1038/nrg2843 PMID: 20661255

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. (2009); 136:215–233. doi: 10. 1016/j.cell.2009.01.002 PMID: 19167326

Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, et al. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. Clin Colorectal Cancer. (2014); 13:37–45. doi: 10.1016/j.clcc.2013.11.006 PMID: 24503111

Fan HM, Sun XY, Guo W, Zhong AF, Niu W, Zhao L, et al. Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. J Psychiatr Res. (2014); 59:45–52. doi: 10.1016/j.jpsychires.2014.08.007 PMID: 25201637

Roy B, Dunbar M, Shelton R C, et al. Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder. Neuropsychopharmacology (2017): 864–875; doi:10.1038/npp.2016.175; published online 5 October 2016

Wan, Y. et al. “Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder,” PLoS ONE, (2015);10(3): 1–12. doi: 10.1371/journal.pone.0121975.

Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med (2011);9: 90.




How to Cite

Ratu, E. (2024). MICRO-RNA AS DIAGNOSTIC MODALITY OF MAJOR DEPRESSIVE DISORDER. Journal of Psychiatry Psychology and Behavioral Research, 5(1), 25–27. https://doi.org/10.21776/ub.jppbr.2024.005.01.5